NYSE: BAKBraskem Sa Stock
$3.72-0.22 (-5.58%)
Updated Apr 30, 2025
BAK Price
$3.72
Fair Value Price
N/A
Market Cap
$1.48B
52 Week Low
$2.85
52 Week High
$9.05
P/E
-0.75x
P/B
-1.79x
P/S
0.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.44B
Earnings
-$1.83B
Gross Margin
7.7%
Operating Margin
-13.11%
Profit Margin
-14.6%
Debt to Equity
-22.14
Operating Cash Flow
$394M
Beta
1.01
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BAK Overview
Braskem SA is the largest petrochemical company in Latin America and the 8th largest resin producer worldwide. The company produces over 16 million tons of thermoplastic resins and other petrochemicals per year. Braskem also produces biopolymers from sugarcane-based ethanol. The company was founded in 2002 and is headquartered in São Paulo, Brazil.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BAK's potential to beat the market
- BAK doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Chemical
Industry Rating
F
BAK
RankedUnranked of 14
RankedUnranked of 14
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.39 | B | |
| $17.24 | B | |
| $4.26 | C |
Be the first to know about important BAK news, forecast changes, insider trades & much more!
BAK News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BAK scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BAK is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BAK is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
BAK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 35 more BAK due diligence checks available for Premium users.
Valuation
BAK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.75x
Industry
43.63x
Market
29.18x
BAK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.79x
Industry
1.12x
BAK's financial health
Profit margin
Revenue
$12.5B
Net Income
-$1.8B
Profit Margin
-14.6%
BAK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BAK's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$16.4B
Liabilities
$17.1B
Debt to equity
-22.14
BAK's short-term assets ($6.43B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BAK's long-term liabilities ($13.47B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BAK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BAK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$394.0M
Investing
-$563.9M
Financing
$75.9M
BAK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BAK vs Chemical Stocks
Braskem Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.